[go: up one dir, main page]

MX2015008333A - Metodos y composiciones para la administracion de oxibutinina. - Google Patents

Metodos y composiciones para la administracion de oxibutinina.

Info

Publication number
MX2015008333A
MX2015008333A MX2015008333A MX2015008333A MX2015008333A MX 2015008333 A MX2015008333 A MX 2015008333A MX 2015008333 A MX2015008333 A MX 2015008333A MX 2015008333 A MX2015008333 A MX 2015008333A MX 2015008333 A MX2015008333 A MX 2015008333A
Authority
MX
Mexico
Prior art keywords
salt
oxybutynin
agents
compositions
methods
Prior art date
Application number
MX2015008333A
Other languages
English (en)
Inventor
Robert Cook
David A Byron
Scott Fleming
Original Assignee
Microdose Therapeutx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/728,706 external-priority patent/US9119777B2/en
Application filed by Microdose Therapeutx Inc filed Critical Microdose Therapeutx Inc
Publication of MX2015008333A publication Critical patent/MX2015008333A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige a métodos y composiciones para tratar enfermedades pulmonares que comprende administrar directamente a los pulmones de los pacientes una cantidad efectiva terapéuticamente de oxibutinina en combinación con uno o más agentes efectivos farmacéuticamente. La oxibutinina puede ser seleccionada del grupo que consiste de, pero no se limita a, una sal de xinafoato, una sal de palmitato, una sal pamoica, una sal de resonato, una sal de laureato y otras sales. Los agentes efectivos farmacéuticamente comprenden broncodilatadores, antinflamatorios, corticosteroides, agentes de inversión de corticosteroides o agentes de crecimiento alveolar, u otros agentes seleccionados de entre inhibidores de proteinasa o proteasa.
MX2015008333A 2012-12-27 2013-12-12 Metodos y composiciones para la administracion de oxibutinina. MX2015008333A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/728,706 US9119777B2 (en) 2008-05-30 2012-12-27 Methods and compositions for administration of oxybutynin
PCT/US2013/074759 WO2014105446A1 (en) 2012-12-27 2013-12-12 Methods and compositions for administration of oxybutynin

Publications (1)

Publication Number Publication Date
MX2015008333A true MX2015008333A (es) 2015-11-09

Family

ID=51021931

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008333A MX2015008333A (es) 2012-12-27 2013-12-12 Metodos y composiciones para la administracion de oxibutinina.

Country Status (15)

Country Link
EP (1) EP2938329A4 (es)
JP (1) JP2016504358A (es)
KR (1) KR20150100902A (es)
CN (1) CN104955444A (es)
AR (1) AR094287A1 (es)
AU (1) AU2013368298B2 (es)
BR (1) BR112015015421A2 (es)
CA (1) CA2895955A1 (es)
EA (1) EA201591218A1 (es)
HK (2) HK1215396A1 (es)
IL (1) IL239623A0 (es)
MX (1) MX2015008333A (es)
NZ (1) NZ628479A (es)
UY (1) UY35230A (es)
WO (1) WO2014105446A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3421049B1 (en) * 2016-02-25 2020-07-29 Hisamitsu Pharmaceutical Co., Inc. Liquid external preparation
CN115667205A (zh) 2020-05-05 2023-01-31 爱普宁公司(特拉华) (r)-盐酸奥昔布宁的多晶形物形式

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1191930A2 (en) * 1999-05-20 2002-04-03 Sepracor Inc. Methods for treatment of asthma using s-oxybutynin
US6339107B1 (en) * 2000-08-02 2002-01-15 Syntex (U.S.A.) Llc Methods for treatment of Emphysema using 13-cis retinoic acid
MXPA05004584A (es) * 2002-10-29 2005-07-26 Pharmacia & Up John Company Ll Compuestos de amonio cuaternario.
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
MX2007004976A (es) * 2004-10-25 2007-06-14 Schering Corp Antagonistas de receptor m1 y/o m3 en combinacion con otros compuestos activos para tratar trastornos respiratorios.
US8415390B2 (en) * 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US20090215734A1 (en) * 2008-02-26 2009-08-27 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
CN102448309A (zh) * 2009-06-16 2012-05-09 谭文 左旋(r)班布特罗在制备治疗呼吸性疾病的吸入性药物制剂和药物组合中的应用
GB0918450D0 (en) * 2009-10-21 2009-12-09 Innovata Ltd Composition
WO2011120779A1 (en) * 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
CA2812952A1 (en) * 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation

Also Published As

Publication number Publication date
AR094287A1 (es) 2015-07-22
UY35230A (es) 2015-01-30
JP2016504358A (ja) 2016-02-12
CA2895955A1 (en) 2014-07-03
EP2938329A4 (en) 2016-08-10
WO2014105446A1 (en) 2014-07-03
NZ628479A (en) 2016-06-24
KR20150100902A (ko) 2015-09-02
HK1215396A1 (zh) 2016-08-26
AU2013368298A1 (en) 2015-07-02
AU2013368298B2 (en) 2016-08-11
EA201591218A1 (ru) 2015-11-30
BR112015015421A2 (pt) 2017-07-11
EP2938329A1 (en) 2015-11-04
CN104955444A (zh) 2015-09-30
HK1216843A1 (zh) 2016-12-09
IL239623A0 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
MX369385B (es) Productos para cicatrizar heridas tisulares.
HK1215934A1 (zh) 肽治疗剂及其使用方法
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
HK1204988A1 (en) Methods and compositions for preventing or treating ophthalmic conditions
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
MX355742B (es) Análogos deuterados del ácido 4-hidroxibutírico.
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2013520405A5 (es)
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
BR112013029246A2 (pt) 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
MY170802A (en) Treatment of pulmonary disease
WO2014099226A3 (en) Personal cleansing compositions containing zinc amino acid/trimethylglycine halide
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
SG10201909122QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
WO2012092458A3 (en) Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof
NZ609719A (en) Pharmaceutical composition
PH12013501855A1 (en) Combination therapies for hematologic malignancies
BR112014010729A2 (pt) métodos para tratamento de ataques de gota
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
WO2013117503A3 (en) Pi3k inhibitors for treating fibrotic diseases
TW201129361A (en) Methods for treating pain
MX2015008333A (es) Metodos y composiciones para la administracion de oxibutinina.
MX336278B (es) Composiciones y metodos para la prevencion y el tratamiento de heridas.